Several activating mutations in the cKIT receptor tyrosine kinase are associated with the development and progression of gastrointestinal stromal tumors (GIST). Treatment of GIST with the tyrosine kinase inhibitor imatinib (Gleevec, STI571; Novartis, Basel, Switzerland) increases patient survival. However, many patients develop resistance to imatinib following initial responses. We sequenced cKIT exons from two patients with GIST after the development of imatinib resistance, revealing a point mutation in kinase domain I (exon 13), Val 654 Ala, which has been associated previously with relapse and resistance. Molecular modeling of cKIT-imatinib complexes shows that this residue is located in the drug-binding site and that the Val 654 Ala mutation disrupts drug binding by removing hydrophobic contacts with the central diaminophenyl ring of imatinib. Loss of these contacts results in a destabilizing effect on two key hydrogen bonds between imatinib and Asp 310 and Thr 670 of cKIT. Calculations based on published crystallography data show an estimated destabilization energy of 2.25 kcal/mol in the Val 654 Ala cKIT compared with wild type. When present on the same cKIT allele as an oncogenic mutation, the Val 654 Ala mutation abolishes imatinib-mediated inhibition of cKIT phosphoactivation in vitro. These results highlight some of the structural and functional consequences of the Val 654 Ala mutation in relapsing imatinib-resistant GIST and emphasize the importance of tumor genetics in drug development and patient-specific cancer treatment regimens. [Mol Cancer Ther 2005;4(12):2008 -15] 
Introduction
Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the gastrointestinal tract and is thought to arise from the interstitial cells of Cajal, the pacemaker cells of the gut (1) . Oncogenic mutations in the transmembrane receptor tyrosine kinase (RTK) cKIT are implicated as an important event in the pathogenesis of up to 90% of all GIST (2, 3) and are also associated with the development of mast cell leukemia (4) and testicular seminoma (5) .
cKIT is a type III RTK containing five extracellular NH 2 -terminal immunoglobulin-like domains and an intracellular split kinase motif that includes ATP-binding and phosphotransferase motifs in kinase domains I and II, respectively (6) . The first two NH 2 -terminal immunoglobulin-like domains confer specificity to the cKIT ligand steel factor/ stem cell factor, and the fourth is associated with receptor dimerization (7) . Following stem cell factor binding and receptor dimerization, tyrosine residues in the juxtamembrane region (JMR) of one cKIT monomer become the substrate for transphosphorylation by the kinase domain of the other monomer (8) . Tyrosine phosphorylation, primarily at Tyr 568 , moves the autoinhibitory JMR out of the ATPbinding/phosphotransferase kinase motif and activates the cKIT kinase domain. In the autoinhibited conformation of cKIT, Trp 557 of the JMR prevents Asp 810 (D), Phe 811 (F), and Gly 812 (G) from forming the DFG motif that is necessary for formation of the kinase-active conformation (9) . Kinaseactive cKIT is responsible for relaying the extracellular signal (stem cell factor binding) to the intracellular compartment (10) . Downstream cKIT signaling involves the phosphatidylinositol 3-kinase (PI3K), mitogen-activated protein kinase (MAPK), and Janus-activated kinase/signal transducers and activators of transcription (JAK/STAT) pathways (11) , which are associated with increased cell proliferation and resistance to apoptosis (12) . Constitutive activation of these pathways via oncogenic mutation is thought to play a critical role in interstitial cells of Cajal transformation and development of GIST (1) .
Numerous reports have described unique mutations in cKIT, which cause constitutive activation of the cKIT kinase domain (6) . The most common (66% of cases) involves abrogation of autokinase inhibition through a deletion in the JMR (exon 11; ref. 3) . Alternative gain-offunction cKIT mutations include point mutations in exon 9 of the dimerization domain (13% of cases), exon 13 of the ATP-binding domain, or exon 17 of the phosphotransferase domain (both <3% of cases; ref. 13 ). Moreover, gene expression studies have shown that cKIT is up-regulated in GIST tumor samples leading to exacerbated downstream signaling (14) . Due to its conspicuous location on the plasma membrane, high frequency of mutation, and key role in oncogenesis, cKIT is an attractive target for the development of small-molecule inhibitors.
Imatinib (Gleevec, STI571, Novartis, Basel, Switzerland) is an inhibitor of RTKs, including platelet-derived growth factor receptor a (PDGFRA), cABL, and cKIT (15) , which was originally developed to treat chronic myeloid leukemia (CML) by blocking the ATP-binding pocket of the mutant kinase produced by the oncogenic BCR-ABL fusion gene (16) . However, it was shortly afterward shown that imatinib can also be used to treat GIST (17) and leads to improved survival (18) . Imatinib-induced tumor shrinkage is thought to result mainly from cKIT inhibition; however, inhibition of related RTKs, such as PDGFRA, could also play a role in the antitumor activity of this drug. Structural studies have shown that imatinib binds to the cKIT kinase domain I and abolishes the kinase-active conformation (9) . Furthermore, imatinib inhibits cKIT phosphorylation and activation in vitro (19) leading to decreased downstream proliferative signals and increased apoptotic activity in GIST cell lines (11, 19) .
Although imatinib treatment represents a major step forward in the management of GIST, most patients develop imatinib resistance, resulting in disease progression (18) . Several point mutations have been identified to associate with imatinib resistance in vitro and in vivo (20) (22, 23) . Recently, a Val 654 Ala mutation in the kinase domain I of the same oncogenic cKIT allele was shown to be associated with imatinib resistance and relapse in GIST patients (24) . These findings highlight the importance of constitutive cKIT signaling in GIST persistence.
In this study, we corroborate the clinical significance of the Val 654 Ala mutation reported previously by Chen et al. and next investigate the structural and functional significance of this mutation in conferring resistance to imatinib. We show through molecular modeling of the imatinib-cKIT complex that Val 654 Ala removes key contacts between the cKIT kinase domain I and imatinib, resulting in decreased binding affinity. Moreover, we show that, although an oncogenic cKIT mutant is inactive in the presence of imatinib, a cKIT allele harboring both the oncogenic mutation and the Val 654 Ala mutation remains constitutively active. These results provide insight into the structural and functional consequences of genetic changes that occur in the development of imatinib-resistant GIST.
Materials and Methods

Clinical Information
Patient A (female; date of birth, March 18, 1942) and patient B (female; date of birth, April 22, 1956 ) were diagnosed with GIST localizing to the stomach, liver, and omental regions and the stomach and omental regions, respectively. Both patients obtained good partial responses on 400 mg/d imatinib (treatment start dates, August 20, 2001 for patient A and August 10, 2001 for patient B). After a period of 12 and 14 months for patients A and B, respectively, both developed progressive disease. Despite increased dosages of imatinib (to 600 and 800 mg/d for patients A and B, respectively), disease progression was unimpeded and both patients eventually succumbed. Both patients provided written informed consent to perform ultrasound-guided biopsies at the time of disease progression to compare cKIT mutational status in the recurrent tumor masses with that of the original surgical diagnostic biopsies.
Genomic Sequence Analysis Genomic DNA was extracted from four paraffinembedded GIST biopsies using QIAamp DNA Mini kits (Qiagen, Inc., West Sussex, United Kingdom) according to the manufacturer's instructions. Individual cKIT exons were amplified to assay mutation status with primers designed to anneal on either side of the exon (Table 1) . PCR product size was determined using DNA 7500 Lab-on-aChip assay on the Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA) according to the manufacturer's instructions. To sequence PCR products, amplicons were run on agarose electrophoresis gels, extracted with QIAquick columns (Qiagen), and cloned into pcDNA3 TOPO (Invitrogen, Paisley, United Kingdom). In all cases, sequencing was done with M13-20 forward sequencing primer and the reverse primer used in the PCR amplification.
cKIT Cloning cDNA for wild-type (WT) cKIT was generously donated by Dr. A. Moses (Oregon Health Sciences University, Portland, OR). Mutant cKIT cDNAs were constructed with the QuikChange Site-Directed Mutagenesis kit (Stratagene, La Jolla, CA) and the following respective primers: constitutively active cKIT mutant (Lys 642 Glu; 5V-GGAAGCCCT-CATGTCTGAACTCGAAGTCCTGAGTTACCTTGG-TAATC and 5V-GATTACCAAGGTAACTCAGGA-CTTCGAGTTCAGACATGAGGGCTTCC), imatinibresistant cKIT mutant (Val 654 Ala; 5V-CCTTGGTAATC- Glu/Val 654 Ala using FuGENE 6 transfection reagent (Roche, East Sussex, United Kingdom) according to the manufacturer's instructions. Twenty-four hours after transfection, the medium was changed to 0.5% fetal bovine serum-DMEM. One day after the medium change, the cells were treated for 4 hours with imatinib (0 -1 Amol/L) and then harvested and washed in PBS. All subsequent procedures were carried out on ice or in a 4jC cold room. The cells were lysed in lysis buffer [20 mmol/L Tris-HCl (pH 8.0), 137 mmol/L NaCl, 10% glycerol, 1% NP40, phosphatase inhibitors cocktails 1 and 2 (1:100 dilution; Sigma), and protease inhibitor cocktail (1:100 dilution; Sigma)] and protein samples (500 Ag) were precleared for 30 minutes with protein G-Sepharose beads (Amersham Pharmacia Biotech Ltd., Uppsala, Sweden) and then centrifuged. Supernatants were incubated with anti-cKIT antibody (sc-17806, Santa Cruz Biotechnology, Santa Cruz, CA) for 2 hours on a rotating platform. Protein G-Sepharose (40 AL) was then added to the mixture and incubated/rotated for a further 1.5 hours. Beads were washed four times with lysis buffer, denatured in SDS loading buffer with hmercaptoethanol, and separated by 8% PAGE. Separated protein was transferred onto polyvinylidene difluoride membrane and immunoblotting was done at 4jC overnight with a horseradish peroxidase -conjugated anti-phosphotyrosine antibody (BD Biosciences, Palo Alto, CA) for phospho-cKIT and an anti-cKIT antibody (sc-17806, Santa Cruz Biotechnology) for input cKIT levels.
Molecular Modeling
General. Molecules were analyzed/visualized using SYBYL 7.0 (Tripos, Inc., St. Louis, MO). Electrostatic charges for the protein and the inhibitor were calculated with the Gasteiger-Hü ckel method (25) . Structures were minimized using the Amber force field (version 7.0 or FF02) with a steepest descent gradient of 200 iterations followed by a conjugate gradient of 0.01 kcal/mol or a maximum of 10K iterations as termination criteria. During minimization, an 8-Å nonbonded cutoff was applied. The same force field and variables were used to calculate binding energies through the DOCK algorithm available in the same software suite.
Homology and Imatinib-Binding Site Construction. A computer model of the cKIT protein tyrosine kinase domain (Gly 601 -Glu 925 ) excluding the kinase insert regions (Cys 691 -Leu 764 ) was generated using the program COMPOSER (26), part of the molecular modeling package SYBYL version 6.92. Two crystal structures from the SYBYL Binary Protein Data Bank (PRODAT) library were selected as templates [i.e., the insulin receptor kinase (1irk; identity, 31.5%) and murine cABL kinase (1iep; identity, 29.5%)]. Both structures contain the activation loop in the inactive conformation and the latter has the inhibitor bound. Based on optimal sequence alignments, the structurally conserved regions were determined by an iterative approach, improving both the multiple alignment and the subsequent structurally conserved region framework by pairwise Needleman and Wunsch dynamic programming procedures with a similarity matrix constructed from inter-C distances. The backbone of each structurally conserved region of cKIT kinase was then built by fitting the corresponding structurally conserved region from one of the known homologues to the appropriate region of the framework. Some of the structurally conserved region had to be extended manually to secure that important features were incorporated in the model. Side chains were added using a knowledge-based approach, taking into account the backbone secondary structure and the side chains at the corresponding residues of the templates. Structurally variable regions of the model were constructed by the loop search algorithm within SYBYL. A few manual interventions were necessary to correct backbone geometry, unacceptable side chain conformations, or local side chain clashes. The software was unable to create an acceptable model of the c-helical region (Ser 628 -His 650 ). The corresponding sequence from insulin receptor kinase (Ser 1035 -His 1057 ) was used as a template after the necessary mutations. The final structure was minimized and submitted for quality control to the WHATIF server. 6 Imatinib Docking. Our cKIT model was aligned with the murine cABL crystal structure and the imatinib molecule was transferred to the model. The inhibitor was assigned AMBER force field atoms and the complex was minimized up to a root mean square gradient of 0.01 kcal/mol (conjugate gradient).
Results
The cKIT Missense Mutation Val 654 Ala Is Present in Relapsing GIST Tumor Biopsies following Initial Response to ImatinibTreatment
Two GIST patients were identified presenting with progressive GISTs following initial tumor regression with imatinib (Table 1; Fig. 1A ). To examine the mutational status of cKIT before and after imatinib treatment in these patients, genomic DNA was extracted from tumor biopsy material and selected cKIT exons were PCR amplified and sequenced. Exons 9, 11 to 14, 16, and 17 were chosen because they encode either intracellular functional domains or peptide sequences homologous with regions of BCR-ABL mutated in imatinib-resistant chronic myeloid leukemia (27) . Paraffin-embedded biopsy material taken before treatment was used as control material. Sequencing for both pretreatment and posttreatment samples showed a 13-residue amino acid deletion in patient A (Val 561 -Asp 573 ) and a 6-residue deletion in patient B (Glu 556 -Val 561 ) located within the juxtamembrane region (data not shown). Sequencing of biopsies taken following imatinib resistance revealed substitution of nucleotide 1,982 of the genomic sequence encoding cKIT from thymine to cytosine in both patients (Fig. 1B) . This substitution corresponds to a missense mutation in the protein sequence, with Val 654 being replaced by alanine. Peptide sequences for members of the type III RTK family (KIT, ABL, FLT-3, and PDGFRA) and representatives from other RTK families [SRC, vascular endothelial growth factor receptor-2 (VEGFR2), insulin receptor (INSR), fibroblast growth factor receptor 1 (FGFR1), and epidermal growth factor receptor (EGFR)] were aligned and Val 654 was found to be highly conserved in these RTKs (Fig. 1C) .
Imatinib/cKIT-Binding Models Show Loss of Stabilizing Contacts in the Val 654 Ala cKIT Mutant Compared with WT cKIT
To investigate the effect of the Val 654 Ala on cKIT protein structure, we created a model of the protein based on the crystal structures of related RTKs. The model was based on insulin receptor kinase and cABL both in the inactive conformation. The choice of these two structures was founded on the assumption that inactive structures contain the most relevant information for building the cKIT-imatinib interaction model. Similar approaches have been used to model the imatinib resistance for other cKIT mutants (28) .
The model required manual construction of the c-helical region of cKIT ( Fig. 2A) . This was necessary because the c-helical region built by COMPOSER was too short and did not present an acceptable conformation for the Glu 640 side chain. Glu 640 forms a critical hydrogen bond with Lys 823 conserved in similar kinases (29) that bridges the c-helix to the h-sheet hinge region. The quality of the final model was assessed and deemed acceptable using the WHATIF software server, with only 9% of the amino acids adopting forbidden Psi/Phi combination in the Ramachadran plot (data not shown). All the main features of an archetypical kinase domain were successfully reproduced ( Fig. 2A) and the conformation of the activation loop was in accordance with related structures of inactivated kinases (30) .
During completion of this work, Mol et al. (31) resolved the coordinates of the cKIT-imatinib complex (Protein Data Bank code 1t46). Our model was in excellent agreement with the crystal structure; however, three weaknesses were identified. The outer P-loop in the N-lobe region was shorter than in the X-ray structure (Fig. 2C) . This problem was due to the inability of the software to correctly align 2B and C) . The crystal structure showed this interaction to be false with Leu 595 , providing the hydrophobic shielding necessary for the pyridine ring in the same coordinates. Finally, the geometry of the Phe 811 interaction with the drug is different (Fig. 2C and D) . In the model, the phenyl ring is accommodated in a k-stacking interaction with the pyrimidine ring, whereas in the crystal structure the pyrimidine ring is slightly further away and its plane is vertical to the phenylalanine ring. All the other interactions, including the hydrophobic contacts of Val 654 , were modeled very well with all the key amino acids located within 0.5 to 2.5 Å of the crystal structure coordinates. The root mean square value for the a-carbon atoms of the drug-binding region was 1.9 Å , indicating a good crystal structure mimicry by the model.
The model indicated that Val 654 interacted with the central diaminophenyl ring of imatinib and contributed significantly to the overall binding energy. Additionally, the hydrophobic bulk of the side chain seems to be necessary to force imatinib in a position where it can form the two key hydrogen bonds to the backbone NH of Asp 810 and the carboxylic group of Glu 640 . The geometry of this bond can be easily disrupted in the presence of the Val 654 Ala mutation as the drug moves closer to the alanine residue (Fig. 2D) . This disruption was observed during minimization where the amide oxygen of imatinib moved out of range from the Asp 810 backbone NH and changed orientation significantly. In a similar fashion, the length of the second crucial hydrogen bond to Thr 670 increased significantly from 1.8 to 2.9 Å . A comprehensive schematic of the contacts between imatinib and the protein is presented in Fig. 2B . The publication of the crystal structure offered the opportunity to quantify our original observations by calculating the relative binding energies of the drug in the WT and the Val 654 Ala mutant form of the receptor. Using established methodology (32, 33) and the cKIT crystal structure data, we obtained a difference of 2.25 kcal/mol between the binding energies of the WT and Val 654 Ala mutant for imatinib ( Table 2 ).
An Intra-allelic Val a series of cKIT mutants were cloned and expressed in HEK 239T cells. We used a 293T cell line to assess the phosphorylation status of cKIT rather than a GIST cell line to avoid masking of results by endogenous cKIT expression. Although previous studies indicate that selected downstream signaling pathways activated by different gain-of-function cKIT mutants may differ, tyrosine phosphorylation of cKIT is a consistent feature for all gain-of-function cKIT mutants (11) , including the Lys 642 Glu mutant (34) . The Lys 642 Glu mutation likely interferes with the kinase autoinhibitory mechanism by removing the key hydrogen bond between Lys 642 and the backbone carbonyl of Thr 574 in the JMR. This interaction is involved in supporting the autoinhibitory peptide under the c-helical region. Thus, the Lys 642 Glu mutant would not require the activating phosphorylation of Tyr 568 because the JMR will be permanently destabilized away from its inhibitory conformation out of the kinase active center. Imatinib does not interact with the JMR when binding to oncogenic cKIT and so should bind cKIt oncogenes with JMR deletions in a similar manner to cKIT Lys 642 Glu. Hence, despite occupying a low percentage of naturally occurring cKIT mutations, the Lys 642 Glu mutant is a useful tool for studying cKIT-imatinib interactions.
After validating transfection and expression of the cKIT constructs (Fig. 3, input lanes) , the activation of cKIT in the presence or absence of imatinib was assessed. Immunoprecipitation of total cKIT followed by Western blotting with a pan-phosphotyrosine horseradish peroxidase -conjugated antibody was used to detect phosphorylated (activated) cKIT levels in each treatment group (Fig. 3) . Whereas phospho-activation of WT Lys 642 Glu mutant cKIT was diminished in the presence of imatinib, cKIT constructs with intra-allelic Val 654 Ala mutations (Val 654 Ala and Lys 642 Glu/Val 654 Ala) remained active despite 1 Amol/L imatinib dosages (Fig. 3) .
Discussion
Recent studies in targeted cancer therapy have illustrated how the mutation status of the target receptor is valuable in predicting tumor response to specific tyrosine kinase inhibitors (35) . For patients with non -small cell lung cancer treated with the anti-EGFR tyrosine kinase inhibitor gefitinib (Iressa, AstraZeneca, Macclesfield, United Kingdom), selected EGFR1 mutations correlate with better therapeutic response (36, 37) . In the context of GIST, specific mutations in cKIT are associated with better initial responses to imatinib (3, 38) . Furthermore, SU11248 (Pfizer, Cambridge, MA; ref. 20) , a tyrosine kinase inhibitor that inhibits VEGFR2, cKIT, PDGFR, and FLT3, has been shown to have clinical benefit in patients that have developed imatinib resistance (39) . Moreover, imatinib resistance is not limited to patients with GIST and was initially reported in CML patients as being linked with specific BCR-ABL mutations (27, 40) . These findings indicate that RTK genotyping in patients would be critical to establishing personalized treatment regimens and may be a successful tool in preventing the development of drug resistance and improving outcomes.
Here, we show that individuals with GIST who initially responded to imatinib developed identical mutations at time of disease progression to that recently described from another single center (24) . This corroborates the importance of the Val 654 Ala mutation in conferring resistance to imatinib. Using the structural information available, we determined how the Val 654 Ala mutation could abolish cKIT inhibition by imatinib. On initial observation, a conservative mutation from valine to alanine should be unlikely to induce any large conformational changes that would render the pocket unsuitable for imatinib binding. However, a detailed inspection of the minimization progression showed that Val 654 stabilizes the position of the central diaminophenyl ring of the drug and rendered imatinib in an optimal position for critical H-bonds with Asp 810 and Thr 670 to form. A further contribution to the effects of the Val 654 Ala mutation could originate from the fact that alanine is unable to shield the central hydrophobic region of the binding pocket from solvent molecules (41) . Water molecules intruding the pocket from this direction would destabilize the protein-drug complex. Our binding energy calculations show that the mutation destabilizes the cKIT-imatinib complex by 2.25 kcal/mol. In terms of differences in the Gibbs free energy of binding
, this represents an unfavorable change in the binding constant between 1 and 2 orders of magnitude (42) . Such a reduction could be sufficient to render imatinib less effective in and both residues are located in the 10 -amino acid region between the c-helix and the hinge loop (Fig. 2D) , regions that are critical in regulation of cKIT activation. The conspicuous location of this residue and observed conservation of Val 654 in type III and other family RTKs indicates that it could be involved in RTK regulatory mechanisms or mutated in other malignancies treated with imatinib.
RTKs occupy an apical position in proliferative and antiapoptotic signaling cascade hierarchies, and oncogenic signals from mutant cKIT have been shown to include several pathways critical to oncogenesis, including MAPK p42/44, AKT, and various STAT pathways (11) . Some of the same pathways can be activated by PDGFRA, which is also a target for imatinib (15) and has been shown to harbor gain-of-function mutations in GIST lacking cKIT mutations (3) . Coupled with the observation that cKIT mutations occur early in GIST development (43) Overcoming the development of therapeutic resistance in tumors requires a diverse arsenal of drugs and administration protocols (44) . Recent studies have indicated that downstream signal transduction may vary based on the cKIT mutant type (11) and that unique gene expression profiles are associated with different cKIT-mutant and PDGFRA-mutant types in GIST (45) . As cKIT and PDGFRA mutations are implicated in the majority of GIST cases (45) , perhaps the most broadly applicable complementary therapeutic to imatinib should also target cKIT and PDGFR to halt vital oncogenic signaling at the source.
The development of new therapeutic cKIT inhibitors requires consideration of how both the active and the inactive conformations of cKIT are bound by the drug. Imatinib does not bind the inactive (autoinhibited) conformation of cKIT, as the piperazine group of imatinib binds in the same region as the juxtamembrane region inhibitory domain and therefore interferes with one of the natural regulatory mechanisms of cKIT (9) . Currently, most drugs under development target the active form of the enzyme (e.g., PP1, OSI930, and SU11248; see Fig. 4) ; however, the development of drugs like PD173955 that bind both inactive and active forms of the enzyme (46, 47) could be more effective as a frontline treatment by delaying the onset of conformation-specific drug resistance mutations. Alternatively, some features of the imatinib molecule could be removed or modified in an effort to address the Val 654 Ala mutation itself and tailor therapeutics to patient cKIT genotype. The introduction of additional interactions in regions presumably unaffected by the Val 654 Ala mutation is one possibility (e.g., replacing the piperazine moiety with a small peptide or peptidomimetic that resembles the autoinhibitory JMR). Such an approach would target two different binding regions of a kinase and should be successful in overcoming mutations that do not alter the equilibrium between active and inactive forms of the kinase. This technique has been used previously to inhibit the active form of insulin receptor kinase and could represent an opportunity to develop effective combination therapies for GIST (48) . Finally, various analogues of imatinib and other inhibitors known to further stabilize the inactive state of similar RTKs (e.g., PD173955; Fig. 4 ; ref. 49) should be tested for efficacy in inactivating both the WT and the Val 654 Ala mutant. The results could provide more information about the effect of a mutation in the binding pocket of cKIT and perhaps offer some insight as to whether there is any functional or therapeutic significance to the highly conserved Val 654 in type III RTKs.
